Silo Pharma, Inc. Income Statement
SILO|5 years of annual SEC 10-K data (FY2019-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 5 fiscal years. All figures from audited SEC 10-K filings.
Silo Pharma, Inc. reported $72,102 in revenue and $4M in net loss for FY2025. Revenue has grown at a 10.1% compound annual rate over the past 6 years.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 0.67 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Revenue | $72.1K | $72.1K | $72.1K | $40.6K | $40.6K |
| Cost of Revenue | $5.8K | $5.8K | $5.8K | $27.4K | $27.4K |
| Gross Profit | $66.3K | $66.3K | $66.3K | $13.2K | $13.2K |
| SG&A Expense | - | - | $227.3K | $87.0K | $76.1K |
| R&D Expense | $2.4M | $845.1K | $1.3M | $26.3K | - |
| Operating Income | -$4.7M | -$3.9M | -$3.6M | -$930.4K | -$594.2K |
| Interest Expense | - | - | $2.2K | $0 | $62.7K |
| Net Income | -$4.4M | -$3.7M | -$3.9M | -$1.0M | -$969.5K |
| EPS (Basic) | -$1.19 | -$1.20 | - | - | - |
| EPS (Diluted) | -$1.19 | -$1.20 | - | -$0.04 | -$0.02 |
| Shares Outstanding | 4.5M | 2.9M | 3.2M | 23.6M | 23.4M |
| Gross Margin | 91.9% | 91.9% | 91.9% | 32.5% | 32.5% |
| Operating Margin | -6526.4% | -5347.4% | -5031.3% | -2293.4% | -1464.8% |
| Profit Margin | -6092.6% | -5132.6% | -5420.9% | -2497.7% | -2389.7% |